**Supplementary Table 1: 2×2 Columnar Table**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Target drug‘s ADEs** | **Other drugs’ ADEs** | **Total** |
| **Target drug** | a | b | a + b |
| **Other drugs** | c | d | c + d |
| **Total** | a + c | b + d | N = a + b + c + d |
|  |  |  |  |

Notes: a, number of cases with target adverse events for target drugs; b, number of cases with other adverse events for target drugs; c, number of cases with the target adverse event for other drugs; d, number of cases with other adverse event for other drugs.

**Supplementary Table 2: Four algorithms for disproportionality analysis and their associated positivity thresholds**

|  |  |  |
| --- | --- | --- |
| **Algorithms** | **Target drug‘s ADEs** | **Positive conditions** |
| **ROR** |  | a ≥ 3  ﻿95%CI (lower limit) > 1 |
|  |
|  |
| **PRR** |  | a ≥ 3  PRR ≥ 2  ≥4 |
|  |
| **BCPNN** |  | IC025>0 |
|  |
| **MGPS** |  | EBGM05>2 |
|  |
|  |

Notes: 95%CI, 95% confidence interval; , chi-squared; IC, information component; IC025, the lower limit of 95% CI; E(IC), the expectation of IC; V(IC), the variance of IC; EBGM, Empirical Bayesian Geometric Mean; EBGM05, the lower limit of 95% CI of EBGM.

**Supplementary Table 3: Some adverse events (AEs) that were not suggested in the drug instructions** (n < 20)

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| SOCs | PTs | Number of reports | ROR (95% Cl) | PRR (χ2) | EBGM (EBGM05) | IC (IC025) |
| Cardiac Disorders | Left Ventricular Dysfunction | 14 | 3.77 ( 2.23 - 6.37 ) | 3.77 ( 28.39 ) | 3.76 ( 2.42 ) | 1.91 ( 0.24 ) |
|  | Cardiopulmonary Failure | 8 | 3.79 ( 1.89 - 7.58 ) | 3.79 ( 16.37 ) | 3.78 ( 2.12 ) | 1.92 ( 0.25 ) |
| Respiratory, Thoracic and Mediastinal Disorders | Nasal Ulcer | 13 | 14.66 ( 8.49 - 25.31 ) | 14.65 ( 163.78 ) | 14.52 ( 9.19 ) | 3.86 ( 2.19 ) |
| Nasal Dryness | 12 | 3.53 ( 2 - 6.22 ) | 3.53 ( 21.68 ) | 3.52 ( 2.19 ) | 1.82 ( 0.15 ) |
| Pleuritic Pain | 6 | 4.34 ( 1.95 - 9.68 ) | 4.34 ( 15.4 ) | 4.33 ( 2.22 ) | 2.12 ( 0.45 ) |
| Hypocapnia | 5 | 24.48 ( 10.12 - 59.23 ) | 24.48 ( 110.82 ) | 24.11 ( 11.51 ) | 4.59 ( 2.92 ) |
| Pleural Thickening | 4 | 10.94 ( 4.09 - 29.26 ) | 10.94 ( 35.87 ) | 10.87 ( 4.77 ) | 3.44 ( 1.77 ) |
| Infections and Infestation | Erysipelas | 16 | 5.78 ( 3.53 - 9.44 ) | 5.77 ( 62.91 ) | 5.76 ( 3.82 ) | 2.52 ( 0.86 ) |
| Clostridial Infection | 9 | 5.15 ( 2.68 - 9.91 ) | 5.15 ( 29.99 ) | 5.13 ( 2.97 ) | 2.36 ( 0.69 ) |
| Pseudomembranous Colitis | 6 | 4.74 ( 2.13 - 10.56 ) | 4.74 ( 17.65 ) | 4.73 ( 2.42 ) | 2.24 ( 0.57 ) |
| Hepatic Infection | 6 | 8.86 ( 3.97 - 19.77 ) | 8.86 ( 41.6 ) | 8.81 ( 4.5 ) | 3.14 ( 1.47 ) |
| Enteritis Infectious | 5 | 5.2 ( 2.16 - 12.51 ) | 5.2 ( 16.89 ) | 5.18 ( 2.49 ) | 2.37 ( 0.71 ) |
| Gastrointestinal Bacterial Infection | 4 | 6.42 ( 2.4 - 17.14 ) | 6.42 ( 18.22 ) | 6.4 ( 2.81 ) | 2.68 ( 1.01 ) |
| Lymphangitis | 3 | 7.13 ( 2.29 - 22.16 ) | 7.13 ( 15.73 ) | 7.1 ( 2.75 ) | 2.83 ( 1.16 ) |
| Enterocolitis Infectious | 3 | 5.75 ( 1.85 - 17.87 ) | 5.75 ( 11.73 ) | 5.73 ( 2.22 ) | 2.52 ( 0.85 ) |
| Gastrointestinal Disorders | Faeces pale | 8 | 6.8 ( 3.4 - 13.63 ) | 6.8 ( 39.41 ) | 6.78 ( 3.79 ) | 2.76 ( 1.09 ) |
| Nervous System Disorders | Noninfective Encephalitis | 3 | 8.08 ( 2.6 - 25.12 ) | 8.08 ( 18.5 ) | 8.04 ( 3.11 ) | 3.01 ( 1.34 ) |
|  | Cerebellar Ataxia | 3 | 5.67 ( 1.83 - 17.63 ) | 5.67 ( 11.5 ) | 5.65 ( 2.19 ) | 2.5 ( 0.83 ) |